Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Pain Management in the Pediatric Emergency Department Veronica Carullo, MD Chief, Pediatric Pain Management Service Cohen Children’s Medical Center March 16, 2011 Disclosures I have no financial relationships or affiliations to disclose. I do not intend to discuss any off-label or investigational use of drugs or products in my presentation. Objectives Overview of pain in children Pediatric pain assessment Pharmacologic and nonpharmacologic approaches to pain management in the ED • Injuries • Procedural pain Background Historically, children and infants received less post-operative and procedural analgesia than adults Well documented that children are often undertreated for pain • Kids were half as likely as adults to receive pain medications in the ED for painful conditions (i.e. fractures, burns, sickle cell pain crises) • 30% kids vs. 60% adults got pain meds Selbst & Clark, Ann Emerg Med, 1990 What distinguishes pain in childhood from adult pain? IASP: “An unpleasant sensory or emotional experience associated with actual or potential tissue damage, or described in terms of such damage.” • The inability to communicate pain verbally in no way negates the possibility that an individual is experiencing pain and in need of treatment. In pediatrics, pain is an “inherent quality of life that appears early in development and serves as a signaling system for tissue damage.” Pain may be modulated by developmental stage, affective state, cognitive state, prior pain experiences, distress or suffering. Cassell. NEJM 306:639,1994 Anand KJS and Craig KD Pain 67: 3, 1996 Barriers to Pediatric Pain Control Belief that children, especially infants, do not feel pain the way adults do Lack of routine pain assessment Lack of knowledge in pain treatment Fear of adverse effects of analgesics, especially respiratory depression and addiction Belief that preventing pain in children takes too much time and effort Pediatrics, 18 (3) 2001 Jeffrey Lawson, 1985 Landmark seminar paper Pain and its effects in the human neonate and fetus, 1987, NEJM. Anand & Hickey. • Called into question the widely held belief that neonates do not have the neurophysiologic apparatus required to experience pain Developmental Anatomy of Pain Cutaneous nociception: sensory terminals are present in the perioral area at 7 wks GA, with spread to all body areas by 20 wks GA Dorsal horn: A fibers enter the spinal cord prior to C fibers at 8-12 wks; A and C fiber territories overlap at birth in the developing substantia gelatinosa Developmental Anatomy of Pain Ascending pain pathways: completely myelinated in the spine and brainstem between 22 and 30 wks GA; myelination extends to thalamus at 30 wks; to cortex at 37 wks-term Descending inhibition: develops post term • Pain sensitivity may be more profound Nervous system less effective at blocking painful stimuli Pain in children is still undertreated By health care professionals • • • • By parents • • Fear of adverse effects - inadequate knowledge of drug dosing and safety across the spectrum of ages Legal concerns about diversion or abuse Inadequate assessment and patient disbelief Costs and availability of medication Lack of adequate instruction by health care professionals Fear of addiction and tolerance By patients themselves • “Suffer in silence” Pediatric Pain Assessment Pain assessment = the crucial first step in managing pain Pain is multidimensional • Includes sensory, affective, cognitive, behavioral, sociocultural, and physiologic dimensions • Interactions of above components explain variations that exist in patients’ response to pain and perception of pain Frequent reassessment just as important Pain Scoring Tools Health care providers need to use ageappropriate validated pain scoring tools • • Child self-report = gold standard • Must use an age-appropriate, reliable, and valid pain tool Infant or young child • May be assessed with behavioral pain tools coupled with a parent report The lower age limit for successful use of a selfreport pain scale is generally 3-4 years old (Hicks et al., 2001; Wong & Baker, 1988) Physiologic measures Provide information about general distress levels but are not sensitive or specific indicators of a child’s pain Should only be used as adjuncts to selfreport and behavior ± parental report Pain in the ED Injuries: contusions, strains, sprains, and fracture Rest and splinting Oral analgesics • Acetaminophen • NSAIDs • Aspirin • Opioids (i.e. Hydrocodone / Oxycodone) • Intravenous analgesics for moderate to severe pain as with displaced fractures Acetaminophen Most commonly used analgesic drug in pediatric practice Centrally-acting prostaglandin synthetase inhibitor Antipyretic and analgesic activity but minimal antiinflammatory effects Highly effective as sole analgesic for mild to moderate pain Synergistic when used in combination with NSAIDs and opioids for moderate to severe pain Oral dosing: 15 mg/kg q 4 hours Rectal dosing: 30-40 mg/kg, followed by 20 mg/kg 6 hours later Daily max: 90 mg/kg children, 80 mg/kg neonates, 60 mg/kg premature infants Non-steroidal anti-inflammatory drugs (NSAIDs) Nonselective inhibitors of peripheral cyclooxygenase (COX) Provide excellent analgesia with good safety margin Children appear to have lower incidence of renal and GI side effects than adults even with chronic administration Except in newborn period, when t1/2 after administration is significantly longer, the pharmacodynamics and pharmacokinetics in children similar to that of adults Dosing guidelines: • Ibuprofen PO 6-10 mg/kg q6h • Naproxen PO 5-6 mg/kg q12h • Ketorolac IV 0.5 mg/kg q6h • Comparable with opiates for treatment of postoperative pain and orthopedic injuries with less sedation and fewer side effects Opioids Most commonly used analgesic for moderate to severe acute pain Marked individual variation in opioid dose requirements; therefore doses must be titrated to effect Come in different levels of potency and efficacy Combined with acetaminophen for synergistic effect Oral dosing guidelines: • • Hydrocodone: 0.1-0.2 mg/kg/dose q4h Oxycodone 0.05-0.1 mg/kg/dose q4h Codeine Codeine Phenanthrene alkaloid derived from morphine • Change in the methyl group on 3 position (substituted for the hydroxyl group) One tenth the potency (analgesic properties) of morphine Prodrug – has very little to no analgesic properties in and of itself • Metabolized in liver by CYP2D6 to become an active morphine metabolite Commonly administered orally in combination with acetaminophen At least 10% of American population does not have enzyme necessary for conversion (genetic polymorphisms) • Not all enzyme systems are turned on at birth • Newborns do not have CYP2D6; therefore, no analgesic properties with codeine, only vomiting Very narrow therapeutic window, so genetic variability in metabolism is more likely to have a relevant clinical effect Morphine Gold standard • Metabolized by liver, excreted by kidney Histamine release can lead to decreased peripheral vascular resistance and hypotension • Only of concern if child has severe injury and showing signs of hypovolemia Full term infants < 3 months have decreased morphine clearance (reduce starting dose by 25-50%) • • Widely studied in infants and children 10-20 hrs in preterm infants and 1-2 hrs in young children Continuous pulse oximetry recommended Children < 11 yrs have higher clearance and larger volume of distribution for morphine and and its glucoronides Dosing: 0.05-0.1 mg/kg IV/SQ q3h Fentanyl Synthetic opioid which is 50-100 times more potent than morphine Highly lipid-soluble with rapid entry into the brain very rapid onset (2-5 minutes) and short duration of action (30-45 minutes) • Eliminated almost entirely by hepatic metabolism Rarely causes hypotension • Excellent choice for injured children with severe pain Can rarely cause chest wall rigidity at high doses (>15 micrograms/kg) • Ideal choice for ED Reversible with naloxone, but succinylcholine may be required Dosing: 2-3 micrograms/kg IV q1h Procedural Pain Patients seldom remember how great a clinician you are, but they DO remember how much or how little they hurt when you were treating them. Procedural Pain Consider the type of procedure, expected duration of pain, the patient and parents involved, and child’s pain history Educate the parents and patients on what to expect Utilize combination of non-pharmacologic and pharmacologic methods maximizing topical/local anesthetics Calm environment Consider anxiolytic/sedation Topical Analgesics Widely used for pain associated with needle pricks, IV placements, lumbar punctures, laceration repairs, and procedures on superficial skin lesions LET Lidocaine Infiltration – Decreasing Pain Buffer with bicarbonate (9:1 mixture) • Decreases pain of injection by neutralizing acidic pH of lidocaine Warm to body temperature Inject slowly! Use smallest gauge needle (30-gauge) Inject directly into wound rather than through intact dermis Anxiolytic + Analgesic Combination Benzodiazepine (Midazolam) + Opiate (Fentanyl or Morphine) • Amnesia, sedation and muscle relaxation Safe and effective in children Likelihood of respiratory depression increases with use of a sedative • Proper precautions to protect the airway must be taken Nitrous Oxide-Oxygen Analgesia Advantages • • • • • • Painless delivery Odorless, tasteless Rapid onset, short duration of action Produces sedation, amnesia and dissociation May be used in young children Safe when mixed with oxygen Disadvantages • • • • • • Fail-safe system required Equipment expensive Scavenger device needed Requires patient cooperation Increased incidence of vomiting Greater personnel demands N2O Self-Administration by a 3-year-old Ketamine hydrochloride PCP derivative; NMDA receptor antagonist Analgesic, amnesic, and sedative properties without loss of protective airway reflexes Causes dissociative amnesia Rapid onset (IV: 1 min, IM: 5-10 min) Dosing: 0.5-2 mg/kg IV or 4-5 mg/kg IM Adverse reactions: Laryngospasm, emergence reactions (less common in children than adults) • • Atropine (0.01 mg/kg) or Glycopyrrolate (0.005 mg/kg) to prevent excess salivation Benzodiazepine may decrease likelihood of emergence reaction Propofol Non-opioid, nonbarbiturate sedative-hypnotic given intravenously for sedation during short procedures Potent sedative with amnesic properties; no analgesic properties Rapid onset of action (3 sec - 1 min) and rapid recovery phase (5-10 minutes) Use outside of OR by non-anesthesiologists controversial Low complication rate comparable to midazolam in one pediatric ED study, but advantage of shorter recovery time with propofol (small sample size)1 Dosing: Initial bolus 1-2 mg/kg, followed by maintenance infusion of 60-100 microgram/kg/min 1Havel et al. Acad Emerg Med 1999 Propofol for ED PSA - Concerns Difficult to titrate to desired sedation endpoints without overshooting to apnea and hypotension Loss of protective airway reflexes during apneic periods likely places patients at increased risk of pulmonary aspiration, especially if positive pressure ventilation administered • Gastric insufflation likely induces passive regurgitation Propofol for ED PSA – Concerns (continued) Patients must be carefully screened for “full stomachs” and difficult airways. Propofol should only be used by providers with in-depth knowledge of its adverse effects and skilled in airway assessments and positive pressure ventilation. When propofol is administered, an experienced provider must be dedicated to administering the sedation, managing the airway and cardiorespiratory status of the patient, and not involved with the procedure being performed. Propofol in ED– future research Prospective, randomized studies of pediatric patients undergoing procedural sedation with propofol in the ED needed to better clarify: • • • Risks of adverse events Effectiveness of distress reduction, amnesia Recovery and post-recovery experiences Etomidate Rapidly-acting intravenous sedative-hypnotic; no analgesic properties Fast onset (15-45 seconds), short duration of action (5-10 minutes) Advantage of maintaining cardiovascular stability Minimal effects on ventilation when used alone, although rapid administration can lead to transient apnea Common side effects: nausea, vomiting, myoclonus Dosing: 0.1-0.2 mg/kg IV Three reports of use in pediatric ED for procedural sedation: • • • Dickinson: Acad Emerg Med,2001 Ruth: Acad Emerg Med, 2001 Vinson: Ann Emerg Med, 2002 Etomidate – future research Prospective, randomized studies of pediatric patients undergoing procedural sedation with etomidate in the ED needed to better clarify: • Standardized protocol • Dose (titrated to effect?) • Analgesic adjunct • Procedure specific • Impact of myoclonus on CT scans, suturing? • Elucidation of risk of apnea, aspiration Dexmedetomidine Selective alpha-2-agonist with analgesic and sedative properties and minimal effect on respiratory drive or cardiac function Preliminary studies in pediatric patients demonstrate it is a safe and effective alternative for children undergoing diagnostic imaging • Associated with a much shorter recovery time and less need for adjuvant sedatives Nonpharmacologic Techniques Effect of environment itself must be considered Presence of child life therapists who are trained in nonpharmacologic techniques for reducing pain is vital Three broad categories: • • • Cognitive Behavioral Physical General Principles of Pediatric Pain Management Anticipate & prevent pain Assessment is a continuous process Reverse the reversible: treat the underlying cause Use multi-modal approach • • Nonpharmacologic Pharmacologic Involve parents Use non-noxious routes Address associated psychosocial distress Pediatrics in Review 2003; 24 (10) Questions??